Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous netakimab in Chinese adults with moderate to severe plaque psoriasis
CTR20241245Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of netakimab in plaque psoriasis, sponsored by BIOCAD. Started Aug 2024; status: completed.
02
Drugs
netakimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20241245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241245.